Search Icon

About

Focusing on young Black gay, bisexual, and other men who have sex with men, this project explored ways to support the uptake of effective HIV prevention and treatment modalities for adolescents and adults.

This project was completed in July of 2019.

In 2018, children ages 13 to 24 made up 21% of all new HIV diagnoses in the United States.

Most new HIV diagnoses among youth (81%) occurred among young gay and bisexual men in 2018.

Young Black and Latinx gay and bisexual men are disproportionately impacted by HIV

Our Work

Through this project, the O’Neill Institute engaged a diverse array of stakeholders and conducted policy analysis to evaluate barriers to and opportunities for increasing the engagement of adolescents and young adults in PrEP research and clinical practice. Additionally, our team initiated a policy dialogue for the future deployment of long-acting agents, which are innovative forms of PrEP and HIV treatment that are under development and do not require daily pill taking. The critical work of this project was supported by a grant from amfAR, the Foundation for AIDS Research. 

Featured Work

cover of Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers Report

amfAR

Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers

Read the reports
close up photo of blue pills

amfAR

Expanding Access to Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults: Models for Addressing Consent, Confidentiality, and Payment Barriers

Read the issue brief

Our Team

Jeff Crowley Headshot

Jeffrey S. Crowley Director

Expert Column

Featured Event

amfAR and the O’Neill Institute hosted a briefing on July 16, 2018 at Georgetown Law in connection with the release of their four reports, “Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers.”